Four-year Data from ILLUMENATE Pivotal Trial Reaffirms Safety Profile of Philips Stellarex Low-dose Drug-Coated Balloon

Tuesday, January 28, 2020 Heart Disease News
Email Print This Page Comment bookmark
Font : A-A+

January 28, 2020

  • Mortality rates similar to standard of care through four years with excellent rate of follow-up compliance
  • Philips Stellarex is the only low-dose Drug-Coated Balloon (DCB) to demonstrate sustained treatment effect and high safety profile through four years 
Amsterdam, the Netherlands and Leipzig, Germany – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the four-year results from the randomized controlled ILLUMENATE Pivotal trial in the U.S. With an excellent follow-up compliance rate of over 95% in a highly complex disease patient cohort, the data show similar mortality rates through four years for patients treated with Stellarex compared to those treated with the current standard of care (plain balloon angioplasty). The results were presented at the Leipzig Interventional Course today, January 28th, by Sean Lyden, MD, Chairman of the Department of Vascular Surgery, Cleveland Clinic (U.S.), and co-Primary Investigator for the ILLUMENATE Pivotal trial [1].

The four-year ILLUMENATE Pivotal trial data are the latest data from a series of trials evaluating the safety and efficacy of the Philips Stellarex .035? low-dose [2] DCB in restoring and maintaining blood flow in the superficial femoral artery and popliteal arteries of patients with peripheral arterial disease. The results were evaluated compared to percutaneous transluminal angioplasty (PTA) treatment with uncoated balloons, the current standard of care.

“The four-year data from the ILLUMENATE Pivotal trial further substantiates the three-year results that were presented at LINC 2019 and published in Circulation in 2019,” said Sean Lyden, MD. “The high compliance follow-up rate further affirms the findings of these data in a complex patient population.”

The study’s patient population is complex with a high proportion suffering from severely calcified lesions. The mortality rate at four years was virtually identical between the two patient groups, at 15.6% for the Stellarex patient group and 15.2% for the control group. Secondary safety outcomes were also similar across the two groups. The four-year data also show a clinically relevant lower rate of clinically-driven target lesion revascularization (CD-TLR) in the Stellarex DCB patient group of 28.2%, vs 34.1% in the control group. CD-TLR is a commonly used indicator of treatment efficacy durability.

“The ILLUMENATE Pivotal four-year data builds on the robust, consistent long-term data of the Stellarex clinical evaluation program,” said Chris Landon, general manager, Image Guided Therapy Devices at Philips. “We continue to make relevant data available to healthcare providers in order to help them make an informed decision on the optimal treatment for often complex disease patients with peripheral arterial disease.”

Featuring Philips EnduraCoat technology, a unique coating consisting of a polyethylene glycol excipient with amorphous and crystalline paclitaxel particles dispersed in it, the Stellarex .035” DCB is unlike any other drug-coated balloon for the treatment of peripheral artery disease. EnduraCoat technology provides efficient drug transfer and effective drug residency coupled with high coating durability and minimal particulate loss, thereby enabling a low therapeutic drug dose.

[1] As the study sponsor, Philips was involved in the study design and data collection but was not involved in the analysis or interpretation of the data. Sean Lyden has a consulting relationship with Philips but has not received financial compensation from Philips with regard to the Pivotal data analysis and presentation.[2] Low-dose DCBs are those that deliver a dose of only 2 micrograms of the drug paclitaxel per square millimeter, which is lower than some other DCBs on the market.

For further information, please contact:

Mark GrovesPhilips Global Press OfficeTel: +31 631 639 916 Email: Twitter: mark_groves

Fabienne van der FeerPhilips Image Guided TherapyTel: +31 622 698 001Email: Twitter: FC_Feer

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 80,000 employees with sales and services in more than 100 countries. News about Philips can be found at


  • Philips Stellarex low-dose drug-coated balloon
Primary Logo

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Diabetes Premium Membership Benefits

News A - Z



Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store